secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2022-05-02T23:59:59+00:00
Accession:  0001564590-22-017065
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma Q1 net loss narrows to $3.3M; initiates strategic review
-----------------------------------------------------------------------

- Net loss of $3.3M ($0.23/share) vs $4.1M ($0.33/share) in Q1 2021, narrowing on lower R&D spend.
- Cash $49.1M as of March 31, 2022, expected to fund operations through mid-2023.
- R&D expenses fell to $2.2M from $2.9M due to completion of rNAPc2 Phase 2b enrollment in Q4 2021.
- Board established Special Committee in April to evaluate strategic options including partnering or other alternatives.
- No revenue reported; clinical-stage biotech focused on genetically targeted cardiovascular therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000156459022017065/0001564590-22-017065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000156459022017065/abio-8k_20220502.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-017065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer